VRTX Vertex Pharmaceuticals
- 396.440
- -1.040-0.26%
Vertex Pharmaceuticals News
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX)
Buy Rating on Vertex Pharmaceuticals: Risinger's Confidence in VX-548's Billion-Dollar Potential and FDA Progress
Buy Rating on Vertex Pharmaceuticals Fueled by Promising IgAN Therapy and Strategic Acquisition
Guggenheim Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Amgen (AMGN)
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals' Hold Rating: Balancing Cystic Fibrosis Success With Uncertain Growth From New Acquisition
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
Analyst Maintains 'Sell' Rating on Vertex Pharmaceuticals Amid Skepticism Over Alpine Acquisition and Early-Stage Data
Maintaining Hold Rating Amid Vertex Pharmaceuticals' Acquisition of Alpine Immune Sciences
Vertex Pharma Upgraded at Evercore on Alpine Immune Deal
Stifel Nicolaus Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals (VRTX) Gets a Buy From Piper Sandler
Vertex Pharmaceuticals Analyst Ratings
Evercore ISI Upgrades Vertex Pharmaceuticals (VRTX) to a Buy
RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Amylyx Pharmaceuticals Inc (AMLX)
Buy Rating Affirmed for Vertex Pharmaceuticals Post Alpine Therapeutics Acquisition
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)
Analysis
Price Target
No Data
